Important Disclaimer This article is for educational purposes only. Retatrutide is an investigational treatment and is not approved for use in the UK or any other country as of July 2026. The information below is based on published clinical trial data and should not be used as medical advice or dosing instructions. Always consult a qualified healthcare professional. Retatrutide and similar peptides are not for human consumption outside of approved clinical settings.
Overview of Retatrutide Dosing in Studies
In clinical trials, retatrutide was given as a once-weekly injection. Researchers used a gradual dose escalation approach. This means participants started on a lower dose and increased it slowly over several weeks. The goal was to help the body adjust and reduce side effects.
The doses studied in the main Phase 3 trials included:
- 4 mg once weekly
- 8 mg once weekly
- 12 mg once weekly
Most people in the trials followed a step-up schedule rather than starting directly on the highest dose.
How Dosing Was Managed in Trials
Clinical studies typically followed this kind of pattern:
- Weeks 1–4: Lower starting dose (often 2 mg or 4 mg)
- Weeks 5–8: Increased to the next level
- Later weeks: Moved up to 8 mg or 12 mg depending on tolerance
This slow increase is common with GLP-1 type medications because it helps manage common side effects such as nausea.
Note: These schedules come from published trial protocols. Individual responses can vary significantly.
Key Points from Trial Data
- Higher doses generally showed greater average weight loss in studies.
- Not everyone tolerated the highest dose (12 mg). Some participants stayed on lower doses.
- Dose escalation was done under close medical supervision in the trials.
- The length of treatment in studies ranged from several months to over a year.
Because retatrutide is still investigational, there are no official approved dosing guidelines available for general use.
Comparison with Other Medications
| Medication | Typical Starting Approach | Highest Studied Dose | Dosing Frequency |
|---|---|---|---|
| Semaglutide | Gradual increase | 2.4 mg | Once weekly |
| Tirzepatide | Gradual increase | 15 mg | Once weekly |
| Retatrutide | Gradual increase (studied) | 12 mg | Once weekly |
Retatrutide’s highest studied dose in recent trials was 12 mg once per week.
Safety Considerations Around Dosing
In the trials, side effects were more common during the first few weeks and when doses were increased. Common effects included nausea, vomiting, and changes in appetite. Because retatrutide also activates the glucagon receptor, some participants experienced effects on heart rate and energy.
Important: Self-adjusting doses or using peptides without medical supervision can be dangerous. Clinical trials are conducted in controlled environments with regular monitoring.
Current Status in the UK
As of July 2026, retatrutide has not been approved by the MHRA. There is no official recommended dose for use in the United Kingdom. Any discussion of dosage is based solely on data from ongoing or completed clinical studies.
People interested in research peptides should only obtain them from suppliers who clearly label products for laboratory research use only.You can explore research peptide options on PeptidesX.uk.
Frequently Asked Questions
What dose was used in the latest retatrutide trials? Studies examined doses up to 12 mg once weekly, with gradual increases from lower starting doses.
Is there a standard dose for everyone? No. In trials, dosing was adjusted based on individual response and tolerance under medical supervision.
Can retatrutide be taken orally? All current studies have used injectable forms. Oral versions are not currently being studied for this medication.
How long were people on retatrutide in the studies? Treatment periods ranged from several months to over 80 weeks in some extension studies.
For more detailed information about retatrutide, read our main guide: [Retatrutide for Weight Management: Complete 2026 UK Guide]